 |
|
|
March 31, 2014
| Torii Pharmaceutical Co., Ltd. |
|
|
| Torii announces Postponement of Price Listing on the NHI Reimbursement List for “CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen” a Sublingual Immunotherapy Drug for Japanese cedar Pollinosis |
|
Torii Pharmaceutical Co., Ltd. (TSE:4551) announced today that the price listing of “CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen” (“CEDARTOLEN” hereinafter), a sublingual immunotherapy drug for Japanese cedar pollinosis, on the National Health Insurance reimbursement list by May will be postponed. CEDARTOLEN was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) on January 17, 2014 and Torii has been preparing to have the price of CEDARTOLEN listed in April or May. Torii will continue its effort to launch CEDARTOLEN in October at the earliest.
This announcement does not lead Torii to a change of its financial outlook for the fiscal year ending March 2014.
Torii expects CEDARTOLEN, as a new therapeutic option, to contribute to the treatment of Japanese cedar pollinosis, and continues its effort for an early launch.
| About CEDARTOLEN |
|
CEDARTOLEN, which is the first sublingual immunotherapy drug approved in Japan, can be administered at home and can relieve patients from the pain associated with subcutaneous injection, compared to subcutaneous immunotherapy that has been performed in the past.
In the Phase III clinical study in patients with Japanese cedar pollinosis in Japan, the CEDARTOLEN was statistically superior to placebo, in lowering the "overall nasal symptom and medication score" at the end of treatment (primary efficacy endpoint). |
|
|
|
|
|
